WI Harper-backed EdiGene has completed an RMB 81.5 million Pre-B2 financing round and announced R&D collaboration of T-cell cancer therapy
WI Harper Group 1 week ago EdiGene Inc., a genetic editing biotechnology company backed by WI Harper Group, announced the successful completion of the Pre-B2 round of financing of RMB 81.5 million. This round of investment was jointly invested by IDG Capital and Lilly Asia Fund. They also announced the launch of a new R&D collaboration effort…